Financial agenda for 2026

Villepinte, November 19, 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and
solutions for medical imaging, is announcing its financial agenda for 2026.



Publications calendar

• 2025 ANNUAL REVENUE
February 05, 2026, after trading


• 2025 ANNUAL RESULTS
March 11, 2026, after trading


• 2026 1ST QUARTER REVENUE
April 23, 2026, after trading


• ANNUAL SHAREHOLDERS’ MEETING
May 22, 2026


• 2026 2ND QUARTER REVENUE
July 23, 2026, after trading


• 2026 FIRST HALF RESULTS
September 15, 2026, after trading


• 2026 3RD QUARTER REVENUE
October 22, 2026, after trading




Contacts:
Guerbet
Jérôme Estampes, Chief Financial Officer + 33 1 45 91 50 00 / jerome.estampes@guerbet.com
Christine Allard, Head of Public Affairs and Communications : +33 6 30 11 57 82 /
christine.allard@guerbet.com
Seitosei.Actifin
Marianne Py, Financial Communication + 33 1 80 48 25 31 / marianne.py@seitosei-actifin.com
Jennifer Jullia, Press +33 1 56 88 11 19 / jennifer.jullia@seitosei-actifin.com
About Guerbet
At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a
global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices,
and digital and AI solutions for diagnostic and interventional imaging. As pioneers in contrast products for 98 years,
with more than 2,905 employees worldwide, we continuously innovate and devote 9% of our revenue to Research
and Development in four centers in France and the United States. Guerbet (GBT) is listed in compartment B of
Euronext Paris and generated revenue of €841m in 2024. For more information, please visit www.guerbet.com.




Contacts:
Guerbet
Jérôme Estampes, Chief Financial Officer + 33 1 45 91 50 00 / jerome.estampes@guerbet.com
Christine Allard, Head of Public Affairs and Communications : +33 6 30 11 57 82 /
christine.allard@guerbet.com
Seitosei.Actifin
Marianne Py, Financial Communication + 33 1 80 48 25 31 / marianne.py@seitosei-actifin.com
Jennifer Jullia, Press +33 1 56 88 11 19 / jennifer.jullia@seitosei-actifin.com